Some of you know I've spent the past ~20 years looking for ways to apply #AgingBiology to improve health (dramatically). Five years ago, what I've learned drove me to start @GordianBio with @leportfr, as a way to cut through biological complexity. Today we're starting to share

Large single-cell atlases have received a lot of attention in the past few years. But we think the field is quietly reckoning with a gap between the scale of these datasets and what we've learned about disease mechanisms from them. The clearest wins have been in autoimmune

Power your home for less. Generate clean energy from the sun and save every month with Tesla Solar.

Kaiser Permanente provides more efficient care than US average. Why aren't there more Kaiser's? @FredTurnerBio boldly pushing for more rational healthcare systems.

If we want aging drugs, we need to be multi-indication-maxxing. Rapamycin and metformin were each first approved for a single indication, then we spent decades before discovering they might have broader longevity drug potential. This pattern is now repeating with GLP-1s. A

Understanding how biology works is limited by not being able to see the sequence of events unfolding inside our bodies. At the American Association for Matrix Biology meeting (#ASMB2025) last week, and discussions about extracellular matrix biomarkers made it apparent how they

Apologies for the @BuckInstitute summit overlap, will check my calendar next time

Detailed version:

Norn Group founder @MartinBJensen on aging clocks: “Think about a wristwatch. [...] If I turn the knob 6 hours, I didn't actually do time travel. I just affected the clock, right? [...] The same thing could be true for the biological aging clocks. [...] you could be changing

"The stakes for the discussion are high because the commercial success drivers for polygenic risk embryo cos are brand and sales, with science as a nice-to-have support. This is because most outcomes of what they are selling are not immediately verifiable."

She knows mine

Nice concrete framing on how AI can actually help treat more diseases, by @MoAlQuraishi, @ElementoLab, @james_y_zou & others. Feels right out of a startup too: "Don't tell me it's not possible, tell me exactly what's blocking it so we can problem solve".

Fingers crossed that abundance-pilling is my partner's love language 🤞

I'll be in San Diego next week for NeurIPS. Ping me if you're there and want to chat AI x Bio/Chem!

More thoughts on biomarkers:

The paper (couldn't find authors on Twitter):

How do you know if an aging clock works? You need three things: replicability across populations, prediction of disease outcomes, and appropriate response to interventions. And to interact with the FDA, you also need interpretability. A new study in Nature Aging gives us a good

This is a useful essay from the @NornGroup outlining a resource for those designing clinical trials for aging The essay highlights the rationale for a phase 3 trial for aging that focuses on time to first disease. From a medical and payer perspective this strategy makes sense.

Your body's degrading scaffold might be aging you. The elastin holding your tissues together was mostly made in development, so damage slowly accumulates as we age, and elastin breakdown products can be detected in the blood. Are these fragments just detritus, or do they

To get your aging drug approved, you need Phase III trials. To get reimbursed by Medicare and insurance companies, your primary endpoint needs to show clear benefits in how patients feel, function, or survive. But "aging" can’t be an endpoint until we define exactly how to

We're rapidly entering a Gerontocene period, where aging's ills start to dominate our economics and social structures. In this world, aging drugs have far higher expected value than single-disease approaches. But aging drugs still don’t have a clean path through Phase III